|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-6-3
|
|
pubmed:abstractText |
G-CSF and GM-CSF both hasten myeloid engraftment post-MA-alloSCT; however, GM-CSF is earlier acting and less expensive. The objective was to evaluate efficacy/safety of sequential administration of GM-CSF followed by G-CSF in children post-MA-alloSCT. From January 2001 to June 2005, 31 children received 32 MA-alloSCT: mean age 6.65 yr; MRD BM or PBSC vs. related or unrelated UCB 11:21; malignant vs. non-malignant disorders 22:10. GM-CSF (250 microg/m(2) IV QD) began on day of stem cell infusion. GM-CSF was switched to G-CSF (10 microg/kg IV QD) when WBC >or= 300/mm(3) x 2 days. G-CSF continued until ANC >or= 2500/mm(3) x 2 days, then tapered to maintain ANC >or= 1000/mm(3). Median time to myeloid engraftment (ANC >or= 500/mm(3) x 3 days) was 17 days [13 days vs. 24 days, MRD BM/PBSC vs. UCB (p < 0.0001)], occurring at a median time of two days after switch to G-CSF. Clinically relevant adverse events were bone pain (n = 8) and large pleural effusion (n = 1). It was estimated that sequential GM-CSF/G-CSF was cost-effective compared with G-CSF alone [cost-savings of $1311/patient ($41,952/study), 2007 Red Book Average Wholesale Price]. In summary, it was demonstrated that sequential administration of GM-CSF/G-CSF post-MA-alloSCT was safe, cost-effective and resulted in prompt myeloid engraftment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1399-3046
|
|
pubmed:author |
pubmed-author:BaldingerLeahL,
pubmed-author:Baxter-LoweLee AnnLA,
pubmed-author:BhatiaMonicaM,
pubmed-author:BradleyMary BrigidMB,
pubmed-author:CairoMitchell SMS,
pubmed-author:CheungYing-KuenYK,
pubmed-author:Del ToroGustavoG,
pubmed-author:FoleySandraS,
pubmed-author:GarvinJamesJ,
pubmed-author:GeorgeDianeD,
pubmed-author:HawksRiaR,
pubmed-author:MilitanoOlgaO,
pubmed-author:MorrisErinE,
pubmed-author:QualterErinE,
pubmed-author:RomanElizabethE,
pubmed-author:SatwaniPrakashP,
pubmed-author:SchwartzJosephJ,
pubmed-author:WaxmanIan MIM,
pubmed-author:WolownikKarenK,
pubmed-author:van de VenCarmellaC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
464-74
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18785912-Adolescent,
pubmed-meshheading:18785912-Child,
pubmed-meshheading:18785912-Child, Preschool,
pubmed-meshheading:18785912-Female,
pubmed-meshheading:18785912-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:18785912-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:18785912-Humans,
pubmed-meshheading:18785912-Immunologic Factors,
pubmed-meshheading:18785912-Infant,
pubmed-meshheading:18785912-Male,
pubmed-meshheading:18785912-Recombinant Proteins,
pubmed-meshheading:18785912-Stem Cell Transplantation,
pubmed-meshheading:18785912-Transplantation, Homologous,
pubmed-meshheading:18785912-Transplantation Conditioning
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
|
|
pubmed:affiliation |
Department of Pediatrics, Columbia University, New York, NY 10032, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
